Gain Therapeutics, Inc.
GANX
$1.72
-$0.11-6.01%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 14.49% | 1.82% | -5.42% | -24.17% | -24.68% |
| Gross Profit | -14.49% | -1.82% | 5.42% | 24.17% | 24.68% |
| SG&A Expenses | 9.02% | -8.36% | -10.82% | -10.26% | -16.89% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 11.79% | -3.16% | -8.00% | -17.92% | -21.02% |
| Operating Income | -11.79% | 3.16% | 8.00% | 17.92% | 21.02% |
| Income Before Tax | -7.65% | 0.07% | 2.89% | 15.12% | 17.21% |
| Income Tax Expenses | 19.70% | 52.85% | 60.41% | 2,680.47% | 1,226.44% |
| Earnings from Continuing Operations | -8.14% | -1.49% | 1.22% | 9.24% | 13.92% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -8.14% | -1.49% | 1.22% | 9.24% | 13.92% |
| EBIT | -11.79% | 3.16% | 8.00% | 17.92% | 21.02% |
| EBITDA | -11.74% | 3.19% | 8.05% | 17.95% | 21.06% |
| EPS Basic | 21.65% | 32.87% | 34.85% | 43.72% | 50.90% |
| Normalized Basic EPS | 22.18% | 34.20% | 36.21% | 47.31% | 52.78% |
| EPS Diluted | 21.65% | 32.87% | 34.85% | 43.72% | 50.90% |
| Normalized Diluted EPS | 22.18% | 34.20% | 36.21% | 47.31% | 52.78% |
| Average Basic Shares Outstanding | 39.43% | 42.35% | 44.20% | 54.59% | 74.48% |
| Average Diluted Shares Outstanding | 39.43% | 42.35% | 44.20% | 54.59% | 74.48% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |